Successful Partnership Between Sanofi and Regeneron

This program covers not only the celebration of the extraordinary partnership and collaboration between Sanofi and Regeneron but also the latest developments in the field of type 2 inflammation of the airways. Our guests Dr Paul Rowe from Sanofi and Dr Yamo Deniz from Regeneron explain why the partnership has proved so successful in terms of products, education and advocacy.

Dr Paul Rowe, Head of Global Medical immunology at Sanofi Enzyme, clarifies the overall mission of Sanofi in focusing on rare diseases, rare blood disorders, MS oncology and immunology. It is Sanofi’s goal to help people with debilitating and complex conditions that are often difficult to diagnose and treat. In collaboration with Regeneron, Sanofi launched the first in class treatment for three chronic and difficult diseases driven by underlying type 2 inflammation.

At Regeneron, Dr Yamo Deniz, Head of Medical immunology, considers the partnership with Sanofi a true alliance with a company that has a global footprint and a great experience & expertise to run the appropriate trials.